| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.03 | 0.5 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.035 | 0.5 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.5 |